您当前的位置：
首页 >
文章列表页 >
Cost-effectiveness analysis of cefiderocol for the treatment of confirmed or suspected carbapenem-resistant Gram-negative bacteria serious infections
更新时间：2026-01-24

    • Cost-effectiveness analysis of cefiderocol for the treatment of confirmed or suspected carbapenem-resistant Gram-negative bacteria serious infections

    • “According to the latest research, the economic feasibility of cefoperazone in treating carbapenem resistant Gram negative bacterial infections in China's healthcare system is insufficient, and the price needs to be reduced to improve accessibility.”
    • ZHONGGUO YAOFANG   Vol. 37, Issue 2, Pages: 192-197(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.02.10    

      CLC： R956

    • Received：14 August 2025，

      Revised：2025-12-31，

      Accepted：06 January 2026，

      Published：30 January 2026

    移动端阅览

  • GONG Yuan,KANG Shuo,HOU Yibing,et al.Cost-effectiveness analysis of cefiderocol for the treatment of confirmed or suspected carbapenem-resistant Gram-negative bacteria serious infections[J].ZHONGGUO YAOFANG,2026,37(02):192-197. DOI： 10.6039/j.issn.1001-0408.2026.02.10.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Analysis of cost-effectiveness of amivantamab combined with chemotherapy in the treatment of EGFR-mutated advanced non-small cell lung cancer
Cost-effectiveness analysis of gonadotropin-releasing hormone analogue combined with recombinant human growth hormone in the treatment of central precocious puberty
Cost-effectiveness analysis of sacituzumab tirumotecan versus single-agent chemotherapy in second-line and later-line treatment for metastatic triple-negative breast cancer​
Clinical evaluation of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention
Cost-effectiveness analysis of apatinib combined with adriamycin for second-line treatment of platinum-resistant recurrent ovarian cancer

Related Author

WANG Xianying
LIANG Miao
LIU Yang
LIU Jianing
LIU Zheng
ZENG Linan
WU Jin
YANG Chunsong

Related Institution

Dept. of Pharmacy， Hebei Medical University Third Hospital
Evidence-based Medicine Center， West China Hospital， Sichuan University
Molecular Translational Medicine Laboratory， Translational Medicine Center， Sichuan University
Dept. of Pediatrics， West China Second Hospital， Sichuan University
West China Clinical Medical College， Sichuan University
0